Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules.

Harper J, Adams KJ, Bossi G, Wright DE, Stacey AR, Bedke N, Martinez-Hague R, Blat D, Humbert L, Buchanan H, Le Provost GS, Donnellan Z, Carreira RJ, Paston SJ, Weigand LU, Canestraro M, Sanderson JP, Botta Gordon-Smith S, Lowe KL, Rygiel KA, Powlesland AS, Vuidepot A, Hassan NJ, Cameron BJ, Jakobsen BK, Dukes J.

PLoS One. 2018 Oct 15;13(10):e0205491. doi: 10.1371/journal.pone.0205491. eCollection 2018.

2.

Modulation of Hepatitis C Virus-Specific CD8 Effector T-Cell Function with Antiviral Effect in Infectious Hepatitis C Virus Coculture Model.

Ojiro K, Qu X, Cho H, Park JJ, Vuidepot A, Lissin N, Molloy PE, Bennett A, Jakobsen BK, Kaplan DE, Riley JL, Chang KM.

J Virol. 2017 Apr 28;91(10). pii: e02129-16. doi: 10.1128/JVI.02129-16. Print 2017 May 15.

3.

Elimination of Latently HIV-infected Cells from Antiretroviral Therapy-suppressed Subjects by Engineered Immune-mobilizing T-cell Receptors.

Yang H, Buisson S, Bossi G, Wallace Z, Hancock G, So C, Ashfield R, Vuidepot A, Mahon T, Molloy P, Oates J, Paston SJ, Aleksic M, Hassan NJ, Jakobsen BK, Dorrell L.

Mol Ther. 2016 Nov;24(11):1913-1925. doi: 10.1038/mt.2016.114. Epub 2016 Jun 6.

4.

Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy.

Raman MC, Rizkallah PJ, Simmons R, Donnellan Z, Dukes J, Bossi G, Le Provost GS, Todorov P, Baston E, Hickman E, Mahon T, Hassan N, Vuidepot A, Sami M, Cole DK, Jakobsen BK.

Sci Rep. 2016 Jan 13;6:18851. doi: 10.1038/srep18851.

5.

Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells.

Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, Grand F, Brewer JE, Gupta M, Plesa G, Bossi G, Vuidepot A, Powlesland AS, Legg A, Adams KJ, Bennett AD, Pumphrey NJ, Williams DD, Binder-Scholl G, Kulikovskaya I, Levine BL, Riley JL, Varela-Rohena A, Stadtmauer EA, Rapoport AP, Linette GP, June CH, Hassan NJ, Kalos M, Jakobsen BK.

Sci Transl Med. 2013 Aug 7;5(197):197ra103. doi: 10.1126/scitranslmed.3006034.

6.

Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors.

McCormack E, Adams KJ, Hassan NJ, Kotian A, Lissin NM, Sami M, Mujić M, Osdal T, Gjertsen BT, Baker D, Powlesland AS, Aleksic M, Vuidepot A, Morteau O, Sutton DH, June CH, Kalos M, Ashfield R, Jakobsen BK.

Cancer Immunol Immunother. 2013 Apr;62(4):773-85. doi: 10.1007/s00262-012-1384-4. Epub 2012 Dec 22.

7.

Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies.

Aleksic M, Liddy N, Molloy PE, Pumphrey N, Vuidepot A, Chang KM, Jakobsen BK.

Eur J Immunol. 2012 Dec;42(12):3174-9. doi: 10.1002/eji.201242606. Epub 2012 Oct 16.

8.

Monoclonal TCR-redirected tumor cell killing.

Liddy N, Bossi G, Adams KJ, Lissina A, Mahon TM, Hassan NJ, Gavarret J, Bianchi FC, Pumphrey NJ, Ladell K, Gostick E, Sewell AK, Lissin NM, Harwood NE, Molloy PE, Li Y, Cameron BJ, Sami M, Baston EE, Todorov PT, Paston SJ, Dennis RE, Harper JV, Dunn SM, Ashfield R, Johnson A, McGrath Y, Plesa G, June CH, Kalos M, Price DA, Vuidepot A, Williams DD, Sutton DH, Jakobsen BK.

Nat Med. 2012 Jun;18(6):980-7. doi: 10.1038/nm.2764.

PMID:
22561687
9.

TCR affinity and specificity requirements for human regulatory T-cell function.

Plesa G, Zheng L, Medvec A, Wilson CB, Robles-Oteiza C, Liddy N, Bennett AD, Gavarret J, Vuidepot A, Zhao Y, Blazar BR, Jakobsen BK, Riley JL.

Blood. 2012 Apr 12;119(15):3420-30. doi: 10.1182/blood-2011-09-377051. Epub 2012 Feb 7.

10.

High affinity soluble ILT2 receptor: a potent inhibitor of CD8(+) T cell activation.

Moysey RK, Li Y, Paston SJ, Baston EE, Sami MS, Cameron BJ, Gavarret J, Todorov P, Vuidepot A, Dunn SM, Pumphrey NJ, Adams KJ, Yuan F, Dennis RE, Sutton DH, Johnson AD, Brewer JE, Ashfield R, Lissin NM, Jakobsen BK.

Protein Cell. 2010 Dec;1(12):1118-27. doi: 10.1007/s13238-010-0144-5. Epub 2011 Jan 8.

11.

Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor.

Varela-Rohena A, Molloy PE, Dunn SM, Li Y, Suhoski MM, Carroll RG, Milicic A, Mahon T, Sutton DH, Laugel B, Moysey R, Cameron BJ, Vuidepot A, Purbhoo MA, Cole DK, Phillips RE, June CH, Jakobsen BK, Sewell AK, Riley JL.

Nat Med. 2008 Dec;14(12):1390-5. doi: 10.1038/nm.1779. Epub 2008 Nov 9.

12.

Crystallization and preliminary X-ray structural studies of a Melan-A pMHC-TCR complex.

Yuan F, Georgiou T, Hillon T, Gostick E, Price DA, Sewell AK, Moysey R, Gavarret J, Vuidepot A, Sami M, Bell JI, Gao GF, Rizkallah PJ, Jakobsen BK.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007 Sep 1;63(Pt 9):758-60. Epub 2007 Aug 25.

13.

Cutting edge: Evidence of direct TCR alpha-chain interaction with superantigen.

Pumphrey N, Vuidepot A, Jakobsen B, Forsberg G, Walse B, Lindkvist-Petersson K.

J Immunol. 2007 Sep 1;179(5):2700-4.

14.

Crystal structures of high affinity human T-cell receptors bound to peptide major histocompatibility complex reveal native diagonal binding geometry.

Sami M, Rizkallah PJ, Dunn S, Molloy P, Moysey R, Vuidepot A, Baston E, Todorov P, Li Y, Gao F, Boulter JM, Jakobsen BK.

Protein Eng Des Sel. 2007 Aug;20(8):397-403. Epub 2007 Jul 20.

PMID:
17644531
15.

Computational design and crystal structure of an enhanced affinity mutant human CD8 alphaalpha coreceptor.

Cole DK, Rizkallah PJ, Boulter JM, Sami M, Vuidepot AL, Glick M, Gao F, Bell JI, Jakobsen BK, Gao GF.

Proteins. 2007 Apr 1;67(1):65-74.

PMID:
17243170
16.

Crystallization and preliminary X-ray structural studies of a high-affinity CD8alphaalpha co-receptor to pMHC.

Cole DK, Rizkallah PJ, Sami M, Lissin NM, Gao F, Bell JI, Boulter JM, Glick M, Vuidepot AL, Jakobsen BK, Gao GF.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2005 Mar 1;61(Pt 3):285-7. Epub 2005 Feb 12.

17.

Directed evolution of human T-cell receptors with picomolar affinities by phage display.

Li Y, Moysey R, Molloy PE, Vuidepot AL, Mahon T, Baston E, Dunn S, Liddy N, Jacob J, Jakobsen BK, Boulter JM.

Nat Biotechnol. 2005 Mar;23(3):349-54. Epub 2005 Feb 20.

PMID:
15723046
18.

Design of soluble recombinant T cell receptors for antigen targeting and T cell inhibition.

Laugel B, Boulter JM, Lissin N, Vuidepot A, Li Y, Gostick E, Crotty LE, Douek DC, Hemelaar J, Price DA, Jakobsen BK, Sewell AK.

J Biol Chem. 2005 Jan 21;280(3):1882-92. Epub 2004 Nov 4.

19.

Amplification and one-step expression cloning of human T cell receptor genes.

Moysey R, Vuidepot AL, Boulter JM.

Anal Biochem. 2004 Mar 15;326(2):284-6. No abstract available.

PMID:
15003572
20.

Novel CD8+ T cell antagonists based on beta 2-microglobulin.

Glick M, Price DA, Vuidepot AL, Andersen TB, Hutchinson SL, Laugel B, Sewell AK, Boulter JM, Dunbar PR, Cerundolo V, Oxenius A, Bell JI, Richards WG, Jakobsen BK.

J Biol Chem. 2002 Jun 7;277(23):20840-6. Epub 2002 Mar 25.

21.

The human CD8 coreceptor effects cytotoxic T cell activation and antigen sensitivity primarily by mediating complete phosphorylation of the T cell receptor zeta chain.

Purbhoo MA, Boulter JM, Price DA, Vuidepot AL, Hourigan CS, Dunbar PR, Olson K, Dawson SJ, Phillips RE, Jakobsen BK, Bell JI, Sewell AK.

J Biol Chem. 2001 Aug 31;276(35):32786-92. Epub 2001 Jul 3.

22.

Peripheral membrane proteins: FYVE sticky fingers.

Driscoll PC, Vuidepot AL.

Curr Biol. 1999 Nov 18;9(22):R857-60. Review.

24.

1H, 15N resonance assignment and three-dimensional structure of CYP1 (HAP1) DNA-binding domain.

Timmerman J, Vuidepot AL, Bontems F, Lallemand JY, Gervais M, Shechter E, Guiard B.

J Mol Biol. 1996 Jun 21;259(4):792-804.

PMID:
8683583

Supplemental Content

Loading ...
Support Center